Hims & Hers raises its sales forecast to $1.46 billion, driven by demand for weight-loss drugs.

Hims & Hers, a wellness platform, has seen its shares rise after raising its sales forecast for the year to $1.46-$1.465 billion, driven by demand for weight-loss drugs like GLP-1s. The company reported $401.6 million in revenue for the third quarter, a 77% increase from last year, and surpassed profitability expectations. With over 2 million subscribers, Hims & Hers plans to introduce a generic GLP-1, Liraglutide, next year amid ongoing supply constraints.

November 04, 2024
12 Articles

Further Reading